BeOne Medicines Ltd. — Director's Dealing 2018

May 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2018-04-30

Reporting Person: Wu Xiaobin (President & GM China)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-30	Ordinary Shares	A	1149899	—	Acquired	1149899	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-30	Share Option (Right to Buy)	$13.05	A	766599	Acquired	2028-04-29	Ordinary Shares (766599)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
American Depositary Shares	17365	Direct
American Depositary Shares	4000	Indirect

Footnotes

F1: Represents securities underlying restricted share units ("RSUs"). 1/5th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F2: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F3: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F4: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.